Glenmark Pharmaceuticals Q3 PAT seen up 27.4% YoY to Rs. 190.8 cr: Prabhudas Lilladher

Net Sales are expected to increase by 5.5 percent Y-o-Y (down 4.3 percent Q-o-Q) to Rs. 2,638.6 crore, according to Prabhudas Lilladher.

January 18, 2021 / 11:11 PM IST

Glenmark-Pharma

live

bselive
nselive

Volume

Todays L/H

Prabhudas Lilladher has come out with its third quarter (October-December’ 20) earnings estimates for the Pharma sector. The brokerage house expects Glenmark Pharmaceuticals to report net profit at Rs. 190.8 crore up 27.4% year-on-year (up 6.7% quarter-on-quarter).

Net Sales are expected to increase by 5.5 percent Y-o-Y (down 4.3 percent Q-o-Q) to Rs. 2,638.6 crore, according to Prabhudas Lilladher.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 60.2 percent Y-o-Y (up 8.1 percent Q-o-Q) to Rs. 343.1 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

TAGS: #Brokerage Recos - Sector Report #Brokerage Results Estimates #earnings #Glenmark Pharmaceuticals #pharma #Prabhudas Lilladher #Result Poll

first published: Jan 18, 2021 11:11 pm